Date/Time: Tuesday, June 30, 2020 at 7 PM EST

 webinar will focus on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T- Cells in High-Risk Non-Hodgkin Lymphoma (NHL). Join our leading experts as they discuss important topics and considerations surrounding CAR T-Cell therapy and patients with High-Risk Non-Hodgkin Lymphoma.

Rationale for CAR T-Cell therapy in patients with lymphoma

Review of CAR T-Cell activity in aggressive lymphoma

Review of CAR T-Cell activity in indolent lymphoma and CLL

Review progress on short term and longer term toxicity of CAR T-Cells

Real-world data compared with results seen on clinical trials

Future directions for CAR T-Cell therapy in NHL

Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer - John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology- Hackensack Meridian School of Medicine at Seton Hall University
Professor of Medicine – Georgetown University
Hackensack, NJ



Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

This OncLive® webinar will focus on the  delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T- Cells in High-Risk Non-Hodgkin Lymphoma. Join us Tuesday, June 30, 2020 at 7 PM EST.

CAR T-Cell Therapy in High-Risk Non-Hodgkin Lymphoma